...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
【24h】

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

机译:空间签名通过PD-1鉴定免疫逸出,作为T细胞/组织细胞的大B细胞淋巴瘤的定义特征

获取原文
获取原文并翻译 | 示例

摘要

T-cell/histiocyte-rich large B-cell lymphoma (TCRLBCL) is an aggressive variant of diffuse large B-cell lymphoma (DLBCL) characterized by rare malignant B cells within a robust but ineffective immune cell infiltrate. The mechanistic basis of immune escape in TCRLBCL is poorly defined and not targeted therapeutically. We performed a genetic and quantitative spatial analysis of the PD-1/PD-L1 pathway in a multi-institutional cohort of TCRLBCLs and found that malignant B cells harbored PD-L1/PD-L2 copy gain or amplification in 64% of cases, which was associated with increased PD-L1 expression (P = .0111). By directed and unsupervised spatial analyses of multiparametric cell phenotypic data within the tumor microenvironment, we found that TCRLBCL is characterized by tumor-immune "neighborhoods" in which malignant B cells are surrounded by exceptionally high numbers of PD-L1-expressing TAMs and PD-1(+) T cells. Furthermore, unbiased clustering of spatially resolved immune signatures distinguished TCRLBCL from related subtypes of B-cell lymphoma, including classic Hodgkin lymphoma (cHL) and DLBCL-NOS. Finally, we observed clinical responses to PD-1 blockade in 3 of 5 patients with relapsed/refractory TCRLBCL who were enrolled in clinical trials for refractory hematologic malignancies (NCT03316573; NCT01953692), including 2 complete responses and 1 partial response. Taken together, these data implicate PD-1 signaling as an immune escape pathway in TCRLBCL and also support the potential utility of spatially resolved immune signatures to aid the diagnostic classification and immunotherapeutic prioritization of diverse tumor types.
机译:富含T细胞/组织细胞的大B细胞淋巴瘤(TCRLBCL)是弥漫性大B细胞淋巴瘤(DLBCL)的一种侵袭性变体,其特征是在一种强大但无效的免疫细胞浸润中出现罕见的恶性B细胞。TCRLBCL中免疫逃逸的机制基础定义不清,也没有针对性的治疗。我们对多机构TCRLBCL队列中的PD-1/PD-L1通路进行了遗传和定量空间分析,发现64%的病例中恶性B细胞携带PD-L1/PD-L2拷贝增加或扩增,这与PD-L1表达增加有关(P=0.0111)。通过对肿瘤微环境中的多参数细胞表型数据进行有针对性和无监督的空间分析,我们发现TCRLBCL的特征是肿瘤免疫“邻域”,其中恶性B细胞被大量表达PD-L1的TAM和PD-1(+)T细胞包围。此外,空间分辨免疫信号的无偏聚类将TCRLBCL与B细胞淋巴瘤的相关亚型区分开来,包括经典霍奇金淋巴瘤(cHL)和DLBCL-NOS。最后,我们观察了参与难治性血液系统恶性肿瘤临床试验(NCT03316573;NCT01953692)的5例复发/难治性TCRLBCL患者中的3例对PD-1阻断的临床反应,包括2例完全反应和1例部分反应。综上所述,这些数据表明PD-1信号是TCRLBCL中的一种免疫逃逸途径,并且也支持空间分辨免疫信号的潜在用途,以帮助对不同肿瘤类型进行诊断分类和免疫治疗优先排序。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号